Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy
Investor webcast to be held on Monday November 3, 2025 at 8:00…
Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy
August 20, 2025 09:48 ET | Source: Keros Therapeutics, Inc. LEXINGTON, Mass.,…
![[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients](https://i1.wp.com/ml-eu.globenewswire.com/media/NTJlMDkyZjktNGMwNi00N2YyLTkyZmQtZTIwMWJlNzgxOWYyLTEwMTI2MjEtMjAyNS0wNi0xNS1lbg==/tiny/F-Hoffmann-La-Roche-Ltd.png?w=420&resize=420,280&ssl=1 "[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients")
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients
After a thorough clinical review, the benefit-risk for the use of Elevidys…
